Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Pfizer Acquires Biohaven for $11.6B

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 19, 2022 8:25am

140 Views

Post# 34694752

RE:RE:RE:Pfizer Acquires Biohaven for $11.6B

yawn muggy no one encluding big pharma wants to buy your junk shares

-----------------------------

Hahaha - Thank God there's no demand for shares. That's perfect for me !!!!

As for Big Pharma - why would they be buying? I don't think you understand the order of events here.

Talk to me after P2 Acute (and a whack of other science initiatives underway).
That's what I care about !

: )

<< Previous

Bullboard Posts

Next >>

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide